US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Conduit Pharmaceuticals Inc.

0.5580

-0.0020-0.36%

Pre-market: 0.5468-0.0112-2.01%09:10 EDT

Volume:241.34K

Turnover:132.88K

Market Cap:6.33M

PE:-0.03

High:0.5600

Open:0.5600

Low:0.5300

Close:0.5600

Loading ...

Overview Company News Filings

ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes

RLI Reports First Quarter 2025 Results

BRIEF-Conduit Pharmaceuticals Files Prospectus To Offer Resale Of Up To 2.2 Mln Shares Of Common Stock By Selling Stockholders

Conduit Pharmaceuticals Files Prospectus Relates to Offer, Resale of up to 2.2 Mln Shares of Common Stock by Selling Stockholders

THOMSON REUTERS

Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR

BRIEF-Conduit Pharmaceuticals Announces Leadership Changes

BRIEF-Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama®

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

THOMSON REUTERS

Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program

BRIEF-Conduit Pharmaceuticals Expands Partnership With Sarborg Limited

Conduit expands parntership with Sarborg

Conduit Pharmaceuticals Expands Partnership With Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization

THOMSON REUTERS

Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization

Conduit Pharmaceuticals Inc - Secures Composition of Matter Patent From Uspto for Azd1656

THOMSON REUTERS

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Oxbridge / SurancePlus to Speak at Uncorrelated Puerto Rico on April 1st

Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets Azd1656, Azd5658, and Azd5904

THOMSON REUTERS

Conduit Pharmaceuticals - Results for Study With Charles River Laboratories Expected in Q2 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CDT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CDT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDT\",,,,,undefined,":{"symbol":"CDT","market":"US","secType":"STK","nameCN":"Conduit Pharmaceuticals Inc.","latestPrice":0.558,"timestamp":1746043200000,"preClose":0.56,"halted":0,"volume":241336,"hourTrading":{"tag":"盘前","latestPrice":0.5468,"preClose":0.558,"latestTime":"09:10 EDT","volume":20604,"amount":11497.0052148,"timestamp":1746105045533},"delay":0,"floatShares":10631952,"shares":11338500,"eps":-20.530598,"marketStatus":"Pre-Mkt","change":-0.002,"latestTime":"05-01 09:11:11 EDT","open":0.56,"high":0.56,"low":0.53,"amount":132883.1251056,"amplitude":0.053571,"askPrice":0.56,"askSize":197,"bidPrice":0.5,"bidSize":280,"shortable":3,"etf":0,"ttmEps":-20.530598,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746106200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.558,"preHourTrading":{"tag":"盘前","latestPrice":0.5468,"preClose":0.558,"latestTime":"09:10 EDT","volume":20604,"amount":11497.0052148,"timestamp":1746105045533},"postHourTrading":{"tag":"盘后","latestPrice":0.5509,"preClose":0.558,"latestTime":"19:51 EDT","volume":16963,"amount":9468.2093,"timestamp":1746057095431},"volumeRatio":0.3550258601732588},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CDT\",,,,,undefined,":{"symbol":"CDT","floatShares":10631952,"roa":"-168.82%","roe":"--","lyrEps":-20.530598,"volumeRatio":0.3550258601732588,"shares":11338500,"dividePrice":0,"high":0.56,"amplitude":0.053571,"preClose":0.56,"low":0.53,"week52Low":0.51,"pbRate":"-0.93","week52High":350,"institutionHeld":0,"latestPrice":0.558,"committee":0.174004,"eps":-20.530598,"divideRate":0,"volume":241336,"delay":0,"ttmEps":-20.530598,"open":0.56,"prevYearClose":6.86,"prevWeekClose":0.5625,"prevMonthClose":0.558,"prevQuarterClose":0.781,"fiveDayClose":0.5565,"twentyDayClose":0.7221,"sixtyDayClose":2.2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CDT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531232980","title":"ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2531232980","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531232980?lang=en_us&edition=fundamental","pubTime":"2025-04-29 00:00","pubTimestamp":1745856000,"startTime":"0","endTime":"0","summary":"Presentations demonstrate the potential of AdoShell for allogenic cell therapy in diabetes without immunosuppression, by delivering pancreatic human islets or iPSCs1. New preclinical data support AdoShell Islets progression toward First-In-Human clinical trial submission in 2025. Data to be presented at the American Diabetes Association’s  85th Scientific Sessions, the International Pancreas and Islet Transplant Association  World Congress, the European Islets Study Group , and the International Society for Cell & Gene Therapy  Annual Meeting. Adocia , a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity , today announced the latest preclinical data from its innovative AdoShell technology platform have been selected for presentations at four upcoming scientific conferences.International Society for Cell & Gene Therapy  2025 Annual Meeting, New Orleans, USA, May 7-10, 2025. Ouarda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adocia-present-data-adoshell-upcoming-160000549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","ADOCY","BK4139","BK4121"],"gpt_icon":0},{"id":"2529668237","title":"RLI Reports First Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529668237","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529668237?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:05","pubTimestamp":1745438700,"startTime":"0","endTime":"0","summary":"On January 15, 2025, RLI executed a two-for-one stock split of common stock. All share and per share data in this release reflect the stock split.\"We are pleased to report continued premium growth and profitability in the first quarter of 2025,\" said RLI Corp. President & CEO Craig Kliethermes. \"Gross premiums written increased 5%, driven by continued momentum in our casualty segment. Strong margins in our property and surety segments contributed to an overall combined ratio of 82.3. Coupled with positive investment returns, this led to a 6% increase in book value since year-end 2024. Our performance highlights the strength and resilience of our diversified, niche specialty portfolio. I am proud of our team’s dedication to our customers and their focus on delivering results for our shareholders.\". RLI achieved $70.5 million of underwriting income in the first quarter of 2025 on an 82.3 combined ratio, compared to $77.7 million on a 78.5 combined ratio in 2024.RLI’s comprehensive earnin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rli-reports-first-quarter-2025-200500622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","RLI","BK4121","CDT"],"gpt_icon":0},{"id":"2529566200","title":"BRIEF-Conduit Pharmaceuticals Files Prospectus To Offer Resale Of Up To 2.2 Mln Shares Of Common Stock By Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2529566200","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529566200?lang=en_us&edition=fundamental","pubTime":"2025-04-23 06:03","pubTimestamp":1745359404,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Files Prospectus To Offer Resale Of Up To 2.2 Mln Shares Of Common Stock By Selling StockholdersApril 22  - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS FILES PROSPECTUS RELATES TO OFFER, RESALE OF UP TO 2.2 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERSSource text: [ID:n0001641172-25-005732]Further company coverage: CDT.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R024F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2529565872","title":"Conduit Pharmaceuticals Files Prospectus Relates to Offer, Resale of up to 2.2 Mln Shares of Common Stock by Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2529565872","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529565872?lang=en_us&edition=fundamental","pubTime":"2025-04-23 05:26","pubTimestamp":1745357165,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R024F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2529067333","title":"Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2529067333","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529067333?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:05","pubTimestamp":1745323500,"startTime":"0","endTime":"0","summary":"Four oral sessions to be presented, including validation data for Shield MCD test, selected for highly anticipated NCI Vanguard Study. 18 total abstracts to showcase significant developments in multiomic profiling with liquid and tissue biopsies across screening, recurrence monitoring and treatment selection. PALO ALTO, Calif., April 22, 2025----Guardant Health, Inc. , a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity smart liquid biopsy platform at the 2025 American Association for Cancer Research  Annual Meeting, April 25-30 in Chicago.An oral presentation of performance data for the Shield MCD test, selected for the National Cancer Institute’s Vanguard Study evaluating emerging multi-cancer detection  technology. Additional oral presentations on methylation-based cancer signal of origin identification,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/guardant-health-present-data-highlighting-120500227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1244550494.USD","BK4196","BK4551","BK4585","LU0417517546.SGD","LU0912757837.SGD","IE0004445015.USD","CDT","BK4581","LU2133065610.SGD","LU1585245621.USD","IE00BJJMRY28.SGD","LU0942090050.USD","IE00B7KXQ091.USD","BK4534","LU1718418525.SGD","BK4504","BK4566","LU2279689827.SGD","LU0795875086.SGD","BK4535","LU0256863811.USD","BK4610","LU1732800096.USD","IE00BFSS7M15.SGD","LU0795875169.SGD","GH","LU0868494617.USD","LU1732799900.SGD","BK4588","LU1244550577.SGD","BK4550","LU1244550221.USD","IE00BJJMRX11.SGD","BK4209","LU2347655156.SGD","MCD","IE00BFSS8Q28.SGD","IE00BJTD4V19.USD","LU1430594728.SGD","LU0868494708.USD","IE00BJTD4N35.SGD","BK4121"],"gpt_icon":1},{"id":"2527114592","title":"BRIEF-Conduit Pharmaceuticals Announces Leadership Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2527114592","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527114592?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:40","pubTimestamp":1744807252,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Announces Leadership ChangesApril 16 (Reuters) - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS ANNOUNCES LEADERSHIP CHANGESCONDUIT PHARMACEUTICALS INC - APPOI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA1RP5HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2526698452","title":"BRIEF-Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama®","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698452","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698452?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:57","pubTimestamp":1744376238,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VtamaApril 11 (Reuters) - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS ANNOUNCES NOVEL COCRYSTAL PATENT FILING FO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP1E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDT","BK4121"],"gpt_icon":0},{"id":"2526698716","title":"Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698716","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698716?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:30","pubTimestamp":1744374600,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA  which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships.This innovative approach differentiates Conduit's intellectual property from existing formulation patents, offering potential partners a next generation tapinarof asset with what the Company estimates to be extensive commercial viability. This comes at a critical juncture for VTAMA, a drug that has demonstrated blockbuster potential through Organon's $1.2 billion acquisition from Dermavant Sciences yet could face imminent generic competition upon exclusivity expiry in 2027. The timing is particularly strategic in the Company’s view, with tapinarof now entering clinical trials for cutaneous lupus and showing promise across multiple other inflammatory and autoimmune indications. Conduit's novel a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-novel-cocrystal-123000026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW","BK4121"],"gpt_icon":0},{"id":"2526669675","title":"Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2526669675","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526669675?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:30","pubTimestamp":1744288201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA5D2YKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2526695845","title":"Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2526695845","media":"GlobeNewswire","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526695845?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:30","pubTimestamp":1744288200,"startTime":"0","endTime":"0","summary":"NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025  -- Conduit Pharmaceuticals Inc.   today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect their underlying value.Under the program, Conduit may repurchase shares from time to time through open market transactions or other methods in compliance with SEC Rule 10b-18. Purchases will be executed by The Benchmark Company, the Company's appointed broker, and will be subject to market conditions, corporate liquidity requirements, regulatory considerations, and other factors.The share repurchase program does not obligate the Company to acquire a particular amount of common stock and the Company will use its discretion to repurchase shares. The program has no fixed expiration date and may be adjusted or terminated at any ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-announces-1-000-123000617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDTTW","BK4121","CDT"],"gpt_icon":0},{"id":"2525043461","title":"BRIEF-Conduit Pharmaceuticals Expands Partnership With Sarborg Limited","url":"https://stock-news.laohu8.com/highlight/detail?id=2525043461","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525043461?lang=en_us&edition=fundamental","pubTime":"2025-04-07 21:07","pubTimestamp":1744031227,"startTime":"0","endTime":"0","summary":"BRIEF-Conduit Pharmaceuticals Expands Partnership With Sarborg LimitedApril 7 (Reuters) - Conduit Pharmaceuticals Inc CDT.O:CONDUIT PHARMACEUTICALS EXPANDS PARTNERSHIP WITH SARBORG LIMITED TO LEVERAGE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2525043487","title":"Conduit expands parntership with Sarborg","url":"https://stock-news.laohu8.com/highlight/detail?id=2525043487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525043487?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:50","pubTimestamp":1744030206,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals (CDT) entered into an additional license and use agreement with Sarborg to expand the scope of work on Conduit’s acquired A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conduit-expands-parntership-with-sarborg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conduit-expands-parntership-with-sarborg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2525107550","title":"Conduit Pharmaceuticals Expands Partnership With Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization","url":"https://stock-news.laohu8.com/highlight/detail?id=2525107550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525107550?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:32","pubTimestamp":1744029132,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL0YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2525488220","title":"Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization","url":"https://stock-news.laohu8.com/highlight/detail?id=2525488220","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525488220?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:30","pubTimestamp":1744029000,"startTime":"0","endTime":"0","summary":"Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways.NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025  -- Conduit Pharmaceuticals Inc.   today announces that it has entered into an additional license and use agreement  withSarborg Limited to expand the scope of work on Conduit’s acquired AstraZeneca assets, includingAZD1656, AZD5658, and AZD5904.Under the agreement,Sarborgwill apply its proprietarymachine learning algorithmsto conduct an in-depth analysis of Conduit’s clinical and safety data, with the goal of uncovering missed insights, identifying potential drug repurposing opportunities, and highlighting gaps in existing datasets. A key focus will be the re-evaluation of historical clinical trial data, including endpoints, to determine whether specific patient subgroups may have demonstrated therapeutic benefits,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-expands-partnership-sarborg-123000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW"],"gpt_icon":0},{"id":"2523949510","title":"Conduit Pharmaceuticals Inc - Secures Composition of Matter Patent From Uspto for Azd1656","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949510?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:35","pubTimestamp":1743424507,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE0VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CDT","BK4121"],"gpt_icon":0},{"id":"2523941750","title":"Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2523941750","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523941750?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424200,"startTime":"0","endTime":"0","summary":"Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025  -- Conduit Pharmaceuticals Inc.   today announces that the United States Patent and Trademark Office  has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent protection now secured, the Company is strategically positioned to advance AZD1656 into clinical development, with clinical trial plans now in final stages of preparation.Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/conduit-pharmaceuticals-receives-u-patent-123000741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDT","CDTTW"],"gpt_icon":0},{"id":"2521747413","title":"Oxbridge / SurancePlus to Speak at Uncorrelated Puerto Rico on April 1st","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747413","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747413?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"GRAND CAYMAN, Cayman Islands, March  24, 2025  (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (Nasdaq: OXBR) (“Oxbridge Re”), together with its subsidiary SurancePlus, is engaged in the tokenization","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047770/0/en/Oxbridge-SurancePlus-to-Speak-at-Uncorrelated-Puerto-Rico-on-April-1st.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDT","OXBR","BK4019","BK4121"],"gpt_icon":0},{"id":"2520858184","title":"Conduit Pharmaceuticals provides R&D upgrade on AZD1656, AZD5658, AZD5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520858184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520858184?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:37","pubTimestamp":1742387827,"startTime":"0","endTime":"0","summary":"Conduit Pharmaceuticals (CDT) provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The Company has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/conduit-pharmaceuticals-provides-rd-upgrade-on-azd1656-azd5658-azd5904?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/conduit-pharmaceuticals-provides-rd-upgrade-on-azd1656-azd5658-azd5904?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2520893691","title":"Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets Azd1656, Azd5658, and Azd5904","url":"https://stock-news.laohu8.com/highlight/detail?id=2520893691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520893691?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA2PXNRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","CDT"],"gpt_icon":0},{"id":"2520892831","title":"Conduit Pharmaceuticals - Results for Study With Charles River Laboratories  Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520892831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520892831?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:30","pubTimestamp":1742387401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA2PXNRD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4530","BK4588","LU0390134368.USD","BK4121","CRL","CDT","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CDT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-27","symbol":"CDT","defaultRemindTime":1737988200000,"type":"split","dateTimestamp":1737954000000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CDT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CDT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CDT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CDT","date":"2025-04-29","current":-0.347124,"percent":0.837912,"low":-460.917103,"twenty":-47.758265,"median":-6.138704,"eighty":-0.54095,"high":-0.0799,"avg":-40.728239,"sd":89.148444,"marketCap":6179495},"quantilePoints":[{"date":"2023-10-13","current":-14.733381,"twenty":-17.829889,"median":-16.48141,"eighty":-15.432593,"marketCap":128180419},{"date":"2023-10-20","current":-14.483663,"twenty":-16.181748,"median":-14.691762,"eighty":-14.550255,"marketCap":126007869},{"date":"2023-10-27","current":-9.739015,"twenty":-15.882086,"median":-14.650142,"eighty":-14.017522,"marketCap":84729429},{"date":"2023-11-03","current":-12.652395,"twenty":-15.199522,"median":-14.483663,"eighty":-12.552508,"marketCap":110075840},{"date":"2023-11-10","current":-10.071973,"twenty":-14.799973,"median":-12.902114,"eighty":-10.821128,"marketCap":87626162},{"date":"2023-11-17","current":-9.745674,"twenty":-14.66679,"median":-12.152959,"eighty":-9.744342,"marketCap":84787364},{"date":"2023-11-24","current":-24.87973,"twenty":-14.683438,"median":-11.487043,"eighty":-9.941453,"marketCap":133977347},{"date":"2023-12-01","current":-63.281053,"twenty":-17.380396,"median":-12.694015,"eighty":-10.221804,"marketCap":340768471},{"date":"2023-12-08","current":-47.866438,"twenty":-32.992686,"median":-14.483663,"eighty":-10.372134,"marketCap":257760767},{"date":"2023-12-15","current":-96.544171,"twenty":-48.488431,"median":-14.650142,"eighty":-10.455207,"marketCap":519890360},{"date":"2023-12-22","current":-67.607963,"twenty":-67.878395,"median":-15.066339,"eighty":-10.588057,"marketCap":364068880},{"date":"2023-12-29","current":-66.255804,"twenty":-68.040654,"median":-16.106832,"eighty":-10.687945,"marketCap":356787502},{"date":"2024-01-05","current":-66.120588,"twenty":-67.716136,"median":-18.728875,"eighty":-10.787832,"marketCap":356059364},{"date":"2024-01-12","current":-60.576735,"twenty":-67.716136,"median":-27.854481,"eighty":-10.887719,"marketCap":326205716},{"date":"2024-01-19","current":-38.130891,"twenty":-67.526833,"median":-37.184379,"eighty":-11.204029,"marketCap":205334848},{"date":"2024-01-26","current":-38.942186,"twenty":-66.82371,"median":-38.942186,"eighty":-11.453747,"marketCap":209703674},{"date":"2024-02-02","current":-35.697004,"twenty":-66.30989,"median":-38.468931,"eighty":-11.886593,"marketCap":192228368},{"date":"2024-02-09","current":-43.742352,"twenty":-66.174674,"median":-38.266107,"eighty":-12.452621,"marketCap":235552565},{"date":"2024-02-16","current":-41.240857,"twenty":-65.71494,"median":-38.468931,"eighty":-12.702339,"marketCap":222082016},{"date":"2024-02-23","current":-38.266107,"twenty":-64.633212,"median":-38.468931,"eighty":-12.868818,"marketCap":206062986},{"date":"2024-03-01","current":-34.750493,"twenty":-63.362183,"median":-38.536539,"eighty":-13.634621,"marketCap":187131404},{"date":"2024-03-08","current":-35.83222,"twenty":-63.226967,"median":-38.198499,"eighty":-14.483663,"marketCap":192956506},{"date":"2024-03-15","current":-42.998664,"twenty":-62.118196,"median":-38.266107,"eighty":-14.550255,"marketCap":231547807},{"date":"2024-03-22","current":-46.649494,"twenty":-58.954144,"median":-38.80697,"eighty":-14.650142,"marketCap":251207527},{"date":"2024-03-28","current":-48.272085,"twenty":-56.303911,"median":-39.212618,"eighty":-14.66679,"marketCap":259945180},{"date":"2024-04-05","current":-44.215608,"twenty":-55.411486,"median":-39.753482,"eighty":-14.799973,"marketCap":238101047},{"date":"2024-04-12","current":-43.13388,"twenty":-54.194543,"median":-40.294346,"eighty":-15.199522,"marketCap":232275945},{"date":"2024-04-19","current":-40.993558,"twenty":-49.732418,"median":-40.835209,"eighty":-15.882086,"marketCap":220750312},{"date":"2024-04-26","current":-427.79731,"twenty":-59.765439,"median":-41.117207,"eighty":-16.930903,"marketCap":228871561},{"date":"2024-05-03","current":-412.617406,"twenty":-65.03886,"median":-41.781721,"eighty":-19.959046,"marketCap":220750312},{"date":"2024-05-10","current":-419.517363,"twenty":-67.256401,"median":-42.187369,"eighty":-24.87973,"marketCap":224441789},{"date":"2024-05-17","current":-89.879435,"twenty":-68.824906,"median":-42.728232,"eighty":-26.06963,"marketCap":217058835},{"date":"2024-05-24","current":-90.49086,"twenty":-78.722712,"median":-42.998664,"eighty":-31.234879,"marketCap":218535426},{"date":"2024-05-31","current":-91.713709,"twenty":-86.822311,"median":-42.998664,"eighty":-32.85747,"marketCap":221488608},{"date":"2024-06-07","current":-85.905174,"twenty":-88.962298,"median":-43.539528,"eighty":-34.750493,"marketCap":207460996},{"date":"2024-06-14","current":-61.753897,"twenty":-87.739448,"median":-43.80996,"eighty":-34.966839,"marketCap":149135662},{"date":"2024-06-21","current":-44.634005,"twenty":-87.066881,"median":-44.080392,"eighty":-35.264314,"marketCap":107791122},{"date":"2024-06-28","current":-31.182661,"twenty":-86.822311,"median":-44.080392,"eighty":-35.020925,"marketCap":75306126},{"date":"2024-07-05","current":-19.568648,"twenty":-86.822311,"median":-43.80996,"eighty":-32.160941,"marketCap":47258285},{"date":"2024-07-12","current":-8.865658,"twenty":-86.822311,"median":-43.336704,"eighty":-24.87973,"marketCap":21410565},{"date":"2024-07-15","current":-8.024949,"twenty":-86.822311,"median":-43.13388,"eighty":-24.87973,"marketCap":19380253},{"date":"2024-08-02","current":-6.267103,"twenty":-86.638884,"median":-43.066272,"eighty":-20.630864,"marketCap":15135054},{"date":"2024-08-09","current":-5.19711,"twenty":-85.477177,"median":-42.998664,"eighty":-16.282943,"marketCap":12551021},{"date":"2024-08-16","current":-2.669983,"twenty":-83.616666,"median":-42.79584,"eighty":-14.799973,"marketCap":15197543},{"date":"2024-08-23","current":-2.782989,"twenty":-82.833276,"median":-42.457801,"eighty":-14.483663,"marketCap":15840775},{"date":"2024-08-30","current":-2.194345,"twenty":-81.616333,"median":-41.849329,"eighty":-12.669043,"marketCap":12490211},{"date":"2024-09-06","current":-2.099892,"twenty":-79.777396,"median":-41.511289,"eighty":-11.403804,"marketCap":11952585},{"date":"2024-09-13","current":-2.329278,"twenty":-74.503975,"median":-40.970425,"eighty":-10.48817,"marketCap":13258248},{"date":"2024-09-20","current":-2.255065,"twenty":-70.177065,"median":-40.294346,"eighty":-9.745674,"marketCap":12835828},{"date":"2024-09-27","current":-2.172418,"twenty":-69.636202,"median":-39.888698,"eighty":-9.018515,"marketCap":12365405},{"date":"2024-10-04","current":-1.66136,"twenty":-68.960122,"median":-39.618266,"eighty":-8.024949,"marketCap":9456462},{"date":"2024-10-11","current":-1.72714,"twenty":-68.284042,"median":-38.942186,"eighty":-5.597593,"marketCap":9830881},{"date":"2024-10-18","current":-1.71196,"twenty":-68.148827,"median":-38.401323,"eighty":-2.782989,"marketCap":9744476},{"date":"2024-10-25","current":-2.062785,"twenty":-67.607963,"median":-38.130891,"eighty":-2.68685,"marketCap":11741374},{"date":"2024-10-31","current":-1.791696,"twenty":-67.49979,"median":-37.590027,"eighty":-2.642322,"marketCap":10198332},{"date":"2024-11-08","current":-1.699632,"twenty":-66.607365,"median":-37.522419,"eighty":-2.434525,"marketCap":9674307},{"date":"2024-11-15","current":-0.683034,"twenty":-66.282847,"median":-37.18438,"eighty":-2.341422,"marketCap":9657424},{"date":"2024-11-22","current":-0.732446,"twenty":-66.147631,"median":-36.711124,"eighty":-2.250005,"marketCap":11097296},{"date":"2024-11-29","current":-0.724301,"twenty":-65.88513,"median":-36.035044,"eighty":-2.191309,"marketCap":10973878},{"date":"2024-12-06","current":-0.642842,"twenty":-65.728158,"median":-35.697004,"eighty":-2.136324,"marketCap":9739703},{"date":"2024-12-13","current":-0.648697,"twenty":-65.557968,"median":-34.885709,"eighty":-2.104952,"marketCap":9828408},{"date":"2024-12-20","current":-0.518958,"twenty":-64.227565,"median":-32.405511,"eighty":-2.070881,"marketCap":7862726},{"date":"2024-12-27","current":-0.460417,"twenty":-63.362183,"median":-30.829231,"eighty":-1.971833,"marketCap":6975772},{"date":"2025-01-03","current":-0.598858,"twenty":-63.25401,"median":-24.87973,"eighty":-1.919522,"marketCap":9073299},{"date":"2025-01-10","current":-0.648697,"twenty":-63.145837,"median":-19.568648,"eighty":-1.895806,"marketCap":9828408},{"date":"2025-01-17","current":-0.583827,"twenty":-61.753897,"median":-17.605142,"eighty":-1.8334,"marketCap":8845567},{"date":"2025-01-24","current":-0.395547,"twenty":-60.812167,"median":-15.982791,"eighty":-1.791603,"marketCap":5992932},{"date":"2025-01-31","current":-0.201729,"twenty":-57.331553,"median":-15.066339,"eighty":-1.741555,"marketCap":3056394},{"date":"2025-02-07","current":-0.122619,"twenty":-55.654875,"median":-14.650142,"eighty":-1.697038,"marketCap":1857808},{"date":"2025-02-14","current":-0.128948,"twenty":-55.330356,"median":-14.483663,"eighty":-1.649553,"marketCap":1953695},{"date":"2025-02-21","current":-0.09414,"twenty":-55.13826,"median":-12.778777,"eighty":-0.882703,"marketCap":1426317},{"date":"2025-02-28","current":-0.088602,"twenty":-53.010523,"median":-12.402677,"eighty":-0.73059,"marketCap":1342416},{"date":"2025-03-07","current":-0.08702,"twenty":-50.521832,"median":-11.403804,"eighty":-0.711674,"marketCap":1318444},{"date":"2025-03-14","current":-0.0799,"twenty":-49.678331,"median":-10.737889,"eighty":-0.666568,"marketCap":1210571},{"date":"2025-03-21","current":-0.211359,"twenty":-49.502551,"median":-10.405763,"eighty":-0.647115,"marketCap":3202300},{"date":"2025-03-28","current":-0.184627,"twenty":-48.933528,"median":-9.908824,"eighty":-0.629809,"marketCap":2797277},{"date":"2025-04-04","current":-0.256525,"twenty":-48.406557,"median":-9.739015,"eighty":-0.621391,"marketCap":4566652},{"date":"2025-04-11","current":-0.400469,"twenty":-48.109826,"median":-8.942087,"eighty":-0.595694,"marketCap":7129147},{"date":"2025-04-17","current":-0.291968,"twenty":-47.947567,"median":-8.781761,"eighty":-0.581358,"marketCap":5197615},{"date":"2025-04-25","current":-0.344257,"twenty":-47.812352,"median":-6.267103,"eighty":-0.56231,"marketCap":6128471},{"date":"2025-04-29","current":-0.347124,"twenty":-47.758265,"median":-6.138704,"eighty":-0.54095,"marketCap":6179495}],"updateTime":1746085982274}}}